Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07851259
PHASE2

A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Sponsor: Genentech, Inc.

View on ClinicalTrials.gov

Summary

This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Official title: A Phase II, Randomized, Double-Masked, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of RO7965032 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

321

Start Date

2026-09-30

Completion Date

2030-08-21

Last Updated

2026-10-01

Healthy Volunteers

No

Interventions

DRUG

RO7965032

RO7965032 will be administered as per the schedule defined in the protocol.

DRUG

Placebo

Placebo will be administered as per the schedule defined in the protocol.